

AMENDMENTS TO THE CLAIMS

1-13. (Canceled)

14. (Previously presented) Recombinantly produced, isolated and purified lipidated PsaA protein having a purity of at least 80%.

15. (Canceled)

16. (Currently amended) An immunological composition comprising the recombinant lipidated PsaA protein of ~~claim 13~~ claim 14 and a pharmaceutically acceptable carrier or diluent.

17. (Original) The immunological composition of claim 16, further comprising an adjuvant.

18. (Original) The immunological composition of claim 17, wherein the adjuvant is alum.

19. (Original) A method of inducing an immunological response in an animal comprising the step of administering to the animal the immunological composition of claim 16.

20. (Previously presented) A method of immunizing a host against pneumococcal infection, which method comprises administering to the host an immunologically effective amount of recombinantly produced, lipidated PsaA, wherein the lipidated PsaA is recombinantly produced in a High Five cell.

21. (Original) The method of claim 20, wherein said administration is effected intranasally.

22. (Previously presented) An immunogenic composition for intranasal administration to a host susceptible to pneumococcal carriage to elicit a protective immunological response against colonization with *Streptococcus pneumoniae* in the nasopharynx, which comprises an immunizing

amount of recombinant lipidated PsaA, or an immunogenic fragment thereof, wherein the lipidated PsaA is recombinantly produced in a High Five cell.

23. (Original) The composition of claim 22, further comprising an adjuvant.

24. (Original) The composition of claim 23, wherein the adjuvant is alum.

25. (Currently amended) A recombinant lipidated PsaA protein encoded by a hybrid nucleic acid molecule comprising a first nucleic acid sequence encoding a signal sequence of a lipoprotein other than PsaA and a second nucleic acid sequence, wherein the second nucleic acid sequence encodes a mature PsaA protein or an immunogenic fragment of a mature PsaA protein, and wherein the first nucleic acid sequence is contiguous with the second nucleic acid sequence.

26. (Previously presented) The recombinant lipidated PsaA protein of claim 25, wherein the signal sequence is the signal sequence of an OspA protein of a Borrelia species.

27. (Previously presented) The recombinant lipidated PsaA protein of claim 25, wherein the lipidated PsaA is produced in a High Five cell.

28-29. (Canceled)

30. (Previously presented) The recombinantly produced, lipidated PsaA protein of claim 14, wherein said protein has a purity of at least 95%.